Results 351 to 360 of about 9,351,193 (388)

Connecting the Dots: Telomere Shortening and Rheumatic Diseases. [PDF]

Biomolecules
Han F, Riaz F, Pu J, Gao R, Yang L, Wang Y, Song J, Liang Y, Wu Z, Li C, Tang J, Xu X, Wang X.   +12 more
europepmc   +1 more source

Rheumatic? A diagnostic decision support tool for individuals suspecting rheumatic diseases: Mixed-methods usability and acceptability study. [PDF]

BMC Rheumatol
Jakobi S, Boy K, Wagner M, May S, Temiz A, Liphardt AM, Araujo E, Carmona L, Knevel R, Schett G, Knitza J, Muehlensiepen F, Morf H.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Early experience of COVID‐19 vaccine‐related adverse events among adolescents and young adults with rheumatic diseases: A single‐center study

International Journal of Rheumatic Diseases, 2022
Considering the concerns regarding the coronavirus disease‐2019 (COVID‐19) vaccine safety among pediatric patients with inflammatory rheumatic diseases (IRD) due to a lack of data, an urgent need for studies evaluating safety profiles of vaccines emerged.
Fatih Haşlak, Aybuke Gunalp, M. N. Cebi, M. Yıldız, A. Adroviç, S. Şahin, K. Barut, O. Kasapcopur   +7 more
semanticscholar   +1 more source

Chemokines in Rheumatic Diseases

Current Drug Targets, 2006
Chemotactic cytokines, termed chemokines, mediate the ingress of leukocytes into the inflamed synovium. In this review, authors discuss the role of the most relevant chemokines and chemokine receptors involved in chronic inflammatory rheumatic diseases.
Szekanecz, Zoltán, Szűcs, Gabriella, Szántó, Sándor, Koch, Alisa E.   +3 more
openaire   +3 more sources

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases

Arthritis & Rheumatology
We provide evidence‐based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs).
S. Johnson, E. Bernstein, M. Bolster, Jonathan H Chung, S. Danoff, Michael D. George, Dinesh Khanna, G. Guyatt, Reza D Mirza, Rohit Aggarwal, Aberdeen Allen, S. Assassi, Lenore Buckley, Hassan A Chami, Douglas S Corwin, P. Dellaripa, R. Domsic, T. Doyle, C. Falardeau, Tracy M Frech, Fiona K Gibbons, M. Hinchcliff, Cheilonda Johnson, J. Kanne, John S. Kim, Sian Yik Lim, Scott M. Matson, Z. McMahan, Samantha J Merck, Kiana Nesbitt, M. Scholand, Lee Shapiro, Christine D Sharkey, Ross Summer, John Varga, Anil Warrier, Sandeep K. Agarwal, D.E. Antin-Ozerkis, Bradford Bemiss, Vaidehi Chowdhary, Jane E Dematte D'Amico, R. Hallowell, Alicia M Hinze, Patil A Injean, Nikhil Jiwrajka, E. Joerns, Joyce S Lee, A. Makol, Gregory C McDermott, Jake G Natalini, J. Oldham, D. Saygin, K. Lakin, Namrata Singh, Joshua J. Solomon, Jeffrey A. Sparks, Marat Turgunbaev, Samera Vaseer, Amy S. Turner, Stacey Uhl, Ilya Ivlev   +60 more
semanticscholar   +1 more source

Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab

Annals of the Rheumatic Diseases, 2020
It is currently unknown whether immunosuppressive and/or immunomodulating agents such as biological disease-modifying antirheumatic drugs (bDMARDs) affect the rate and the outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections
H. Schulze-Koops, K. Krueger, I. Vallbracht, R. Hasseli, A. Skapenko   +4 more
semanticscholar   +1 more source

Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19

Annals of the Rheumatic Diseases, 2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of COVID-19, which has affected more than 6 million people worldwide causing more than 400 000 deaths.
P. Vlachoyiannopoulos, E. Magira, H. Alexopoulos, E. Jahaj, Katerina Theophilopoulou, A. Kotanidou, A. Tzioufas   +6 more
semanticscholar   +1 more source